1611. Real-World Effectiveness and Tolerability of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Treatment-Experienced People With HIV and a History of Antiretroviral Drug Resistance Mutations
Authors: Trottier Benoit , Bonnet Fabrice , Garcia-Deltoro Miguel , Andreoni Massimo , Boffito Marta , van Welzen Berend J , Turner Dan , McConkey Sam , Watanabe Dai , Lu Po-Liang , Gündüz Alper , Thorpe David , D’Antoni Michelle L , Cassidy Tali , Marongiu Andrea , Weinberg Amy R , Haubrich Richard , Scholten Stefan 
Published: November 2023

Background

BICSTaR is an ongoing, multinational, observational cohort study evaluating the real-world effectiveness and safety of B/F/TAF in antiretroviral therapy (ART) treatment-naïve and treatment-experienced (TE) people with HIV.

Methods

This analysis of BICSTaR included TE virologically suppressed people with HIV who had started B/F/TAF in clinical practice with/without present/past evidence of HIV drug primary resistance mutations (PRMs). All had viral load (VL) data at baseline (BL). We report virologic and other outcomes at 12 months (M).

Results

In the overall population, the most common ARTs taken immediately before B/F/TAF were E/C/F/TAF (27%), DTG+F/TAF (9%) and ABC/DTG/3TC (8%). BL genotypic drug resistance testing data were available for 441/996 (44%) participants (ppts); most tests were historic and performed &gt; 60M before starting B/F/TAF (Table 1).

Of 441 ppts with BL resistance data, 105/441 (24%) had present/past evidence of PRMs: 13% to NRTI, 11% to NNRTI, 6% to PI, 0.2% to INSTI. The most common PRMs were M184V/I (39 [37%]), ≥ 1 thymidine analog mutation (TAM; 40 [38%]), K103N/S in reverse transcriptase (23 [22%]) and M46I/L in protease (13 [12%]). Primary resistance to &gt; 1 ART drug class was observed in 40 (38%) ppts with PRMs. Ppts with preexisting PRMs were older (≥ 50 years), had more prior ARTs and more prior virologic failure, and had a longer time between HIV diagnosis and starting B/F/TAF versus those without PRMs.

At 12M, effectiveness (HIV-1 RNA &lt; 50 copies/mL; missing VL data = excluded) was maintained in 78 (99%) and 739 (98%) ppts with, versus without, any BL PRMs, respectively; 32/33 (97%) of those with M184V/I alone; 13/13 (100%) with M184V/I + 1–2 TAMs; and 2/2 (100%) with M184V/I + ≥ 3 TAMs at BL. No treatment-emergent PRMs to B/F/TAF were reported. Drug-related adverse events (DRAEs) occurred in 17 (16%) ppts with PRMs versus 113 (13%) without PRMs; serious DRAEs occurred in 2 ppts, both had PRMs at BL. Overall, 98/996 (10%) ppts switched from B/F/TAF to other ARTs (15 [14%] with PRMs, 83 [9%] without PRMs). Additional outcomes are shown in Table 2.

Conclusion

After 12 months, virologically suppressed people with HIV initiating B/F/TAF in routine clinical practice maintained high rates of effectiveness despite the presence of PRMs (including M184V/I).

Disclosures

Benoit Trottier, MD, Gilead: Advisor/Consultant|Gilead: Honoraria|Merck: Advisor/Consultant|Merck: Honoraria|ViiV: Advisor/Consultant|ViiV: Honoraria Fabrice Bonnet, PhD, Gilead: Grant/Research Support|Gilead: Honoraria|Gilead: Educational Miguel Garcia-Deltoro, MD, PhD, AbbVie: Advisor/Consultant|AbbVie: Grant/Research Support|Gilead: Advisor/Consultant|Gilead: Grant/Research Support|Janssen: Board Member|Janssen: Grant/Research Support|MSD: Advisor/Consultant|MSD: Grant/Research Support|ViiV: Advisor/Consultant|ViiV: Grant/Research Support Massimo Andreoni, MD, Gilead: Advisor/Consultant|Moderna: Advisor/Consultant|MSD: Advisor/Consultant Marta Boffito, MD, PhD, FRCP, AstraZeneca: Honoraria|ATEA: Advisor/Consultant|ATEA: Honoraria|Gilead: Advisor/Consultant|Gilead: Grant/Research Support|Gilead: Honoraria|GSK: Advisor/Consultant|GSK: Grant/Research Support|Moderna: Grant/Research Support|MSD: Advisor/Consultant|MSD: Grant/Research Support|MSD: Honoraria|Novavax: Grant/Research Support|Pfizer: Advisor/Consultant|Pfizer: Grant/Research Support|Roche: Advisor/Consultant|Roche: Grant/Research Support|Valneva: Grant/Research Support|ViiV: Advisor/Consultant|ViiV: Grant/Research Support Berend J. van Welzen, MD, PhD, Gilead: Advisor/Consultant|Gilead: Grant/Research Support|ViiV: Advisor/Consultant Dan Turner, MD, Gilead: Advisor/Consultant|Gilead: Honoraria|GSK: Advisor/Consultant|GSK: Honoraria Dai Watanabe, MD, PhD, Gilead Sciences K.K.: Honoraria|Janssen Pharmaceutical K.K.: Honoraria|MSD K.K.: Honoraria|ViiV Healthcare K.K.: Honoraria Alper Gündüz, MD, Gilead: Advisor/Consultant|Gilead: Honoraria|GSK: Advisor/Consultant|GSK: Honoraria|MSD: Advisor/Consultant|MSD: Honoraria David Thorpe, PhD, Gilead: Employment|Gilead: Stocks/Bonds Michelle L. D’Antoni, PhD, Gilead: Employment|Gilead: Stocks/Bonds Tali Cassidy, PhD, Gilead: Employment|Gilead: Stocks/Bonds Andrea Marongiu, PhD, Gilead: Employment|Gilead: Stocks/Bonds Amy R. Weinberg, DNP, MS, Gilead: Employment|Gilead: Stocks/Bonds Richard Haubrich, MD, Gilead: Employment|Gilead: Stocks/Bonds Stefan Scholten, MD, AbbVie: Advisor/Consultant|AbbVie: Honoraria|Cepheid: Grant/Research Support|Cepheid: Honoraria|Gilead: Advisor/Consultant|Gilead: Grant/Research Support|Gilead: Honoraria|Gilead: Congress and travel support|GSK: Grant/Research Support|Janssen: Advisor/Consultant|Janssen: Honoraria|Janssen: Congress support|ViiV: Advisor/Consultant|ViiV: Grant/Research Support|ViiV: Honoraria|ViiV: Congress and travel support